Dr. Berger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
233 Needham St. Suite 300
Newton, MA 02464Phone+1 617-293-7738
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1979 - 1982
Boston University Medical CenterInternship, Internal Medicine, 1976 - 1977
Penn MedicinePost-Doctoral Fellowship, 1976 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1976
Certifications & Licensure
MA State Medical License 1982 - 2025
WI State Medical License 2014 - 2021- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Cytopathology
Awards, Honors, & Recognition
- Diamond Award Harvard Pilgrim Healthcare, 1995
- Peer Recognition Award Harvard Pilgrim HealthCare, 1993
Publications & Presentations
PubMed
- 46 citationsDetection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.Barry M Berger, Glenn J Hanna, Marshall R Posner, Eric M Genden, Julio Lautersztain
Clinical Cancer Research. 2022-10-03 - 9 citationsNegative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.Glenn J Hanna, Scott A Roof, Jamie Jabalee, Eleni M Rettig, Rocco Ferrandino
Clinical Cancer Research. 2023-10-13 - 120 citationsThe stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.David A. Ahlquist, William R. Taylor, Douglas W. Mahoney, Hongzhi Zou, Michael J. Domanico
Clinical Gastroenterology and Hepatology. 2012-03-01
Journal Articles
- Multitarget Stool DNA Testing for Colorectal-Cancer Screening,Imperiale TF, Ransohoff, Itzkowitz DF, Levin TR, Lavin P Lidgard GP, Ahlquist DA, Berger BM, N Engl J Med, 4/3/2014
Press Mentions
Naveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual MeetingSeptember 28th, 2024- Naveris Collaborators Present Award-Winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-Driven CancersOctober 24th, 2022
- Mayo Clinic Collaborates with Naveris to Advance Precision Medicine in HPV-Driven Head and Neck Cancer with NavDx in DART 2.0 Clinical TrialApril 13th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
